Genzyme to purchase rest of IG Laboratories
This article was originally published in Clinica
Executive Summary
Genzyme's takeover of IG Laboratories has been approved by IG Labs' independent shareholders some seven months after Genzyme first proposed to buy the remaining shares in a stock swap (see Clinica No 642, p 14). Genzyme already owns around 70% of IG Labs whose shareholders will receive 0.1201 Genzyme General Division stock or around $7 for each IG Labs share held.
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
FDA Holding February Public Meeting On Using AI In Radiology
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: